Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > You better Read Those Rules Yourself

<< Previous

Bullboard Posts

Next >>

Comment by davgroon Dec 05, 2022 9:15pm

131 Views

Post# 35152381

RE:You better Read Those Rules Yourself

Duster340 wrote: you are about to have some posts on the vibe board removed

Good luck with that. I understand the new SH content rules fully and completely.

Some food for thought. You know it's really hard to have your voice heard on Stockhouse bullboards when you force so many members to put you on IGNORE. It's not too late to clean up your act and be a productive and mature contributor to this forum. Push the reset button. Just a suggestion that I know will probably fall on deaf ears.

<< Previous

Bullboard Posts

Next >>

Catch up with companies that got a Stanley Cup Playoffs boost